Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ADVM

Adverum Biotechnologies Inc

Dec 08 • 04:00PM ET

4.36

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB BMRN CRSP NBIX IONS NTLA SGMO MGTX

| Held by: VTI VXF MSSM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.57	Insider Own	48.19%	Shs Outstand	22.00M	Perf Week	3.81%
Market Cap	96.27M	Forward P/E	-	EPS next Y	-5.25	Insider Trans	-7.96%	Shs Float	16.46M	Perf Month	1.87%
Enterprise Value	159.15M	PEG	-	EPS next Q	-1.63	Inst Own	25.52%	Short Float	2.65%	Perf Quarter	25.65%
Income	-184.79M	P/S	-	EPS this Y	-17.07%	Inst Trans	-	Short Ratio	0.61	Perf Half Y	46.80%
Sales	0.00M	P/B	-	EPS next Y	32.32%	ROA	-120.47%	Short Interest	0.44M	Perf YTD	-6.64%
Book/sh	-2.53	P/C	3.69	EPS next 5Y	-	ROE	-417.79%	52W High	6.12 -28.76%	Perf Year	-27.33%
Cash/sh	1.18	P/FCF	-	EPS past 3/5Y	23.61% 8.03%	ROIC	-672.63%	52W Low	1.78 144.94%	Perf 3Y	-35.69%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-48.91% 31.95%	Gross Margin	-	Volatility	2.15% 1.96%	Perf 5Y	-96.82%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-42.12%	Oper. Margin	-	ATR (14)	0.13	Perf 10Y	-95.84%
Dividend Ex-Date	-	Quick Ratio	0.65	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	58.20	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.65	EPS Q/Q	-56.09%	SMA20	3.35%	Beta	0.91	Target Price	5.00
Payout	-	Debt/Eq	-	Sales Q/Q	-100.00%	SMA50	-1.22%	Rel Volume	0.00	Prev Close	4.36
Employees	155	LT Debt/Eq	-	Earnings	Nov 06	SMA200	25.49%	Avg Volume	716.52K	Price	4.36
IPO	Jul 31, 2014	Option/Short	Yes / No	EPS/Sales Surpr.	11.67% -	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-25-24	Initiated	Oppenheimer	Outperform	$25
Apr-30-24	Initiated	H.C. Wainwright	Buy	$30
Jul-07-22	Upgrade	Truist	Hold → Buy	$4
Jul-23-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-03-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Apr-29-21	Downgrade	Truist	Buy → Hold	$30 → $9
Apr-29-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6
Apr-29-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$5
Dec-16-20	Initiated	UBS	Neutral	$13
Nov-12-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-26-20	Downgrade	Raymond James	Mkt Perform → Underperform
May-13-20	Initiated	RBC Capital Mkts	Outperform	$24
May-05-20	Upgrade	SunTrust	Hold → Buy	$13 → $21
Apr-28-20	Initiated	Goldman	Buy	$17
Mar-16-20	Initiated	SVB Leerink	Outperform	$17
Feb-10-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$20
Feb-10-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$8 → $21
Oct-15-19	Reiterated	Chardan Capital Markets	Neutral	$6 → $10
Sep-13-19	Reiterated	Chardan Capital Markets	Neutral	$10 → $6

Show Previous Ratings

Dec-09-25 08:28AM	Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition (PR Newswire)
Dec-04-25 11:42AM	LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock (Zacks)
Dec-03-25 12:16PM	March Biosciences Designates Dr. Gurpreet Ratra as Chief Business Officer (Exec Edge)
Dec-01-25 07:00AM	Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly (GlobeNewswire)
Nov-20-25 07:05AM	Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales (Zacks)
06:18PM	Loading…
Nov-19-25 06:18PM	Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-18-25 04:27AM	The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum (Zacks)
Nov-17-25 07:08AM	Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ (Zacks)
Nov-12-25 05:18PM	Adverum Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
Nov-11-25 10:08AM	Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
Oct-30-25 12:57PM	Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales (Zacks)
Oct-27-25 01:01PM	HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
09:52AM	Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings (Zacks)
08:16AM	Eli Lilly buys Adverum in eye disease gene therapy punt (Pharmaceutical Technology)
Oct-24-25 10:46AM	Eli Lilly to buy Adverum, General Dynamics stock hits new record (Yahoo Finance Video)
08:30AM	Loading…
08:30AM	Lilly to Acquire Adverum Biotechnologies (PR Newswire)
07:44AM	Adverum, hammered by gene therapy downturn, sells to Lilly in unusual deal (BioPharma Dive)
Sep-30-25 07:30AM	2 Penny Stocks That Wall Street Believes Can Soar Over 200% (Barchart)
Sep-22-25 08:00AM	Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration (GlobeNewswire) -7.98%
Sep-21-25 09:12AM	Trexquant Slashes Stake in Adverum Biotechnologies, Inc. (ADVM) (Insider Monkey)
Sep-05-25 04:01PM	Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.04%
Aug-12-25 02:04PM	Adverum Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance) +10.27%
07:00AM	Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights (GlobeNewswire)
Aug-06-25 04:01PM	Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Jul-15-25 07:00AM	Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream (GlobeNewswire)
Jul-14-25 04:47AM	Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 \| Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape (GlobeNewswire) +7.48%
Jun-05-25 04:01PM	Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.94%
May-14-25 04:33PM	Adverum Biotechnologies: Q1 Earnings Snapshot (Associated Press Finance) -7.00%
04:05PM	Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights (GlobeNewswire)
May-02-25 04:01PM	Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:58PM	Loading…
Apr-24-25 01:58PM	Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and More (Insider Monkey)
Apr-15-25 07:47AM	Adverum Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance) -5.83%
07:40AM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones (GlobeNewswire)
Apr-04-25 04:05PM	Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.96%
Mar-31-25 04:01PM	Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire) -5.21% -12.36%
Mar-03-25 04:01PM	Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD (GlobeNewswire) -11.68%
Feb-28-25 04:00PM	Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Feb-25-25 07:00AM	Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference (GlobeNewswire) +9.66%
Feb-05-25 04:05PM	Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-06-24 04:05PM	Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-24 04:05PM	Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.81%
Nov-18-24 07:00AM	Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements (GlobeNewswire)
Nov-15-24 04:05PM	Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements (GlobeNewswire) -5.38%
Nov-04-24 06:00PM	Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
05:06PM	Adverum Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:39PM	Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones (GlobeNewswire)
Oct-16-24 08:00AM	Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program (GlobeNewswire) +6.76%
Oct-11-24 12:00PM	Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Sep-05-24 07:30AM	Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:05PM	Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences (GlobeNewswire)
Sep-03-24 09:55AM	Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High? (Zacks)
Aug-12-24 04:35PM	Adverum Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights (GlobeNewswire)
Aug-02-24 07:00AM	Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.55%
Aug-01-24 08:00AM	Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD (GlobeNewswire)
Jul-18-24 09:40AM	Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? (Zacks) +7.97%
Jul-17-24 02:45AM	Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet (Zacks)
Jul-10-24 08:00AM	Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting (GlobeNewswire)
Jun-18-24 08:00AM	Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit (GlobeNewswire) -9.97%
Jun-11-24 08:00AM	Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilard Kiss as a Member of the Board of Directors (GlobeNewswire)
08:00AM	Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szil rd Kiss as a Member of the Board of Directors (GlobeNewswire)
May-10-24 03:36PM	Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress (GuruFocus.com)
09:35AM	Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
May-09-24 11:55PM	ADVM Stock Earnings: Adverum Biotechnologies Misses EPS for Q1 2024 (InvestorPlace)
05:45PM	Adverum Biotechnologies: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights (GlobeNewswire)
May-03-24 08:00AM	Adverum Biotechnologies to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-02-24 10:01AM	Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-30-24 07:39AM	HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target (MT Newswires)
Apr-29-24 08:33AM	Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating (MT Newswires)
Apr-25-24 04:05PM	Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting (GlobeNewswire) -7.85%
Apr-23-24 09:40AM	Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? (Zacks)
Apr-19-24 09:35AM	Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
Apr-04-24 09:40AM	Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? (Zacks)
08:34AM	How Adverum (ADVM) Stock Stands Out in a Strong Industry (Zacks)
Apr-03-24 09:35AM	Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround (Zacks)
Mar-27-24 09:35AM	Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
Mar-21-24 07:52AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Mar-20-24 05:33AM	Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments (GuruFocus.com) -7.88%
Mar-19-24 09:40AM	Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? (Zacks) -6.78%
Mar-18-24 10:53PM	ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023 (InvestorPlace)
04:20PM	Adverum Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates (GlobeNewswire)
Mar-06-24 03:07PM	Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop (InvestorPlace)
Feb-28-24 04:05PM	Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-27-24 06:10AM	Stocks on the Launchpad: The Next 3 Market Sensations (InvestorPlace)
Feb-22-24 06:15AM	Unleash Massive Returns With These 3 Top Penny Stocks (InvestorPlace) +6.60%
Feb-12-24 08:00AM	Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +15.03%
Feb-08-24 07:00AM	Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD (GlobeNewswire) -29.89%
Feb-05-24 07:45AM	Adverum Biotechnologies Announces $127.5 Million Private Placement Financing (GlobeNewswire) +34.51%
Feb-01-24 05:30PM	Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024 (GlobeNewswire) +13.33% +19.33%
Jan-29-24 08:00AM	Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer (GlobeNewswire) +13.89%
Jan-04-24 08:27AM	Here's Why You Should Invest in Adverum (ADVM) Stock Now (Zacks) +6.00%
Dec-07-23 04:05PM	Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society (GlobeNewswire) +9.43% -10.88%
Nov-28-23 04:05PM	Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire)
Nov-09-23 04:51PM	Adverum Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights (GlobeNewswire)
Nov-06-23 08:00AM	Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors (GlobeNewswire)
Nov-04-23 05:54PM	Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 (GlobeNewswire)

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fischer Laurent	CEO, PRESIDENT AND DIRECTOR	Dec 09 '25	Option Exercise	4.20	150,000	630,000	351,513	Dec 10 01:52 PM
Rubinstein Linda M	CHIEF FINANCIAL OFFICER	Dec 09 '25	Option Exercise	4.20	48,750	204,750	61,150	Dec 10 01:41 PM
Fischer Laurent	CEO, PRESIDENT AND DIRECTOR	Dec 08 '25	Buy	4.31	117,614	506,916	201,513	Dec 08 09:45 PM
Fischer Laurent	CEO, PRESIDENT AND DIRECTOR	Dec 05 '25	Buy	4.24	11,085	47,000	83,899	Dec 08 09:45 PM
Soparkar Peter	CHIEF OPERATING OFFICER	Dec 05 '25	Buy	4.22	50,000	211,000	80,189	Dec 08 09:45 PM
Leonard Braden Michael	10% Owner	Dec 04 '25	Sale	4.19	524,560	2,200,372	1,958,080	Dec 05 06:20 PM
Leonard Braden Michael	10% Owner	Dec 01 '25	Sale	4.20	300,000	1,260,000	2,757,526	Dec 03 09:39 PM
Leonard Braden Michael	10% Owner	Dec 03 '25	Sale	4.17	222,925	929,597	2,428,640	Dec 03 09:39 PM
Leonard Braden Michael	10% Owner	Dec 02 '25	Sale	4.20	51,961	218,236	2,705,565	Dec 03 09:39 PM
Soparkar Peter	CHIEF OPERATING OFFICER	May 15 '25	Sale	2.00	2,960	5,920	39,154	May 16 04:46 PM
Seyedkazemi Setareh	CHIEF DEVELOPMENT OFFICER	May 15 '25	Sale	2.00	924	1,848	13,768	May 16 04:45 PM
Fischer Laurent	CEO, PRESIDENT AND DIRECTOR	May 15 '25	Sale	2.00	9,126	18,252	87,488	May 16 04:44 PM
Leonard Braden Michael	10% Owner	Mar 26 '25	Buy	5.04	20,407	102,841	125,207	Apr 28 03:24 PM
Leonard Braden Michael	10% Owner	Mar 27 '25	Buy	5.19	16,593	86,089	141,800	Apr 28 03:24 PM
Leonard Braden Michael	10% Owner	Apr 22 '25	Buy	3.00	300,000	900,000	3,057,526	Apr 24 09:35 AM
Leonard Braden Michael	10% Owner	Apr 23 '25	Buy	2.98	50,000	148,950	191,800	Apr 24 09:35 AM
Leonard Braden Michael	10% Owner	Mar 31 '25	Buy	4.38	19,566	85,668	2,742,317	Apr 02 06:07 PM
Leonard Braden Michael	10% Owner	Apr 02 '25	Buy	4.04	15,209	61,408	2,757,526	Apr 02 06:07 PM
Leonard Braden Michael	10% Owner	Mar 26 '25	Buy	5.04	20,407	102,841	125,207	Mar 27 07:06 PM
Leonard Braden Michael	10% Owner	Mar 18 '25	Buy	4.69	62,341	292,418	2,667,161	Mar 20 08:02 PM
Leonard Braden Michael	10% Owner	Mar 20 '25	Buy	5.61	30,600	171,767	2,722,761	Mar 20 08:02 PM
Leonard Braden Michael	10% Owner	Mar 19 '25	Buy	4.94	25,000	123,390	2,692,161	Mar 20 08:02 PM
Leonard Braden Michael	10% Owner	Feb 26 '25	Buy	4.01	164,886	660,979	2,432,950	Feb 28 04:04 PM
Leonard Braden Michael	10% Owner	Feb 28 '25	Buy	4.60	85,068	391,015	2,604,820	Feb 28 04:04 PM
Leonard Braden Michael	10% Owner	Feb 27 '25	Buy	4.46	86,802	387,094	2,519,752	Feb 28 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADVM

Adverum Biotechnologies Inc

Upgrade your FINVIZ experience